ARS Pharmaceuticals SPRY
NASDAQ SPRY
$4.37 -0.03 (-0.68%)
As of: Sep 30, 2026 · 10:02 AM EDT

ARS Pharmaceuticals (SPRY) Short term Debt (2020 - 2021)

Updated

ARS Pharmaceuticals (SPRY) posted Short term Debt of $495,000 for Q1 2021, down 41.4% from the prior quarter.

Analysis

ARS Pharmaceuticals (SPRY) Short term Debt (2020 - 2021) Analysis & Trends

At the end of FY2020, ARS Pharmaceuticals' Short term Debt came in at $844,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 ARS Pharmaceuticals 410.68 Mn 266.88 Mn 20.81 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 495,000.00
Dec 31, 2020 844,000.00
API Access

ARS Pharmaceuticals Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=SPRY&period=max&api_key=YOUR_API_KEY